Cite
HARVARD Citation
Harreiter, J. et al. (2021). Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24‐week, prospective, randomized, placebo‐controlled pilot trial. Diabetes, obesity & metabolism. 23 (5), pp. 1129-1139. [Online].